Just caught wind that Palvella is dropping Phase 3 data on their rapamycin treatment today. The stock already jumped like 5% overnight, so people are clearly watching this closely. They're calling it QTORIN, basically a topical gel form of rapamycin designed to hit those microcystic lymphatic malformations directly on the skin. Never heard of this condition before? It's actually pretty rough - rare vascular thing with fluid-filled cysts that causes pain, swelling, infections. No FDA-approved drugs for it yet, which is why this matters. The company's been working on their QTORIN platform to deliver rapamycin more effectively to affected tissues. Stock closed Monday at $87.84 and then climbed to $93.01 in after-hours trading. They're supposed to release the topline results around 6:30 am ET, then host a call at 8 am to discuss everything. Curious to see if the data lives up to the hype. These rare disease plays can be pretty volatile depending on how the trial went.